Literature DB >> 23611439

Statistical power considerations for a utility endpoint in observer performance studies.

Craig K Abbey1, Frank W Samuelson, Brandon D Gallas.   

Abstract

RATIONALE AND
OBJECTIVES: The purpose of this investigation is to compare the statistical power of the most common measure of performance for observer performance studies, area under the ROC curve (AUC), to an expected utility (EU) endpoint.
MATERIALS AND METHODS: We have modified a well-known simulation procedure developed by Roe and Metz for statistical power analysis in receiver operating characteristic (ROC) studies. Starting from a set of baseline simulations, we investigate the effects of three parameters that describe properties of the observers (iso-utility slope, unequal variance, and tendency to favor more aggressive or conservative actions) and three parameters that affect experimental design (number of readers, number of cases, and fraction of positive cases).
RESULTS: The EU endpoint generally has good statistical power relative to AUC in our simulations. Of 396 total conditions simulated, EU had higher statistical power in 377 cases (95%). In 246 of these cases, EU power was 5 percentage points or more higher than AUC. In simulation runs evaluating the effect of the number of readers and cases on the baseline simulations, EU measure had equivalent power to AUC with fewer readers (9% to 28%) or fewer cases (18% to 41%).
CONCLUSION: These simulation studies provide further motivation for considering EU in studies of screening mammography technology and they motivate investigations of utility in other diagnostic tasks.
Copyright © 2013 AUR. All rights reserved.

Mesh:

Year:  2013        PMID: 23611439     DOI: 10.1016/j.acra.2013.02.008

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  8 in total

1.  Generalized Roe and Metz receiver operating characteristic model: analytic link between simulated decision scores and empirical AUC variances and covariances.

Authors:  Brandon D Gallas; Stephen L Hillis
Journal:  J Med Imaging (Bellingham)       Date:  2014-09-25

2.  Determining Roe and Metz model parameters for simulating multireader multicase confidence-of-disease rating data based on real-data or conjectured Obuchowski-Rockette parameter estimates.

Authors:  Stephen L Hillis; Brian J Smith; Weijie Chen
Journal:  J Med Imaging (Bellingham)       Date:  2022-07-08

3.  MATLAB toolbox for ROC analysis of multi-reader multi-case diagnostic imaging studies.

Authors:  Brian J Smith; Stephen L Hillis
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2022-04-04

4.  Identical-test Roe and Metz simulation model for validating multi-reader methods of analysis for comparing different radiologic imaging modalities.

Authors:  Stephen L Hillis
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2022-04-04

5.  A Utility/Cost Analysis of Breast Cancer Risk Prediction Algorithms.

Authors:  Craig K Abbey; Yirong Wu; Elizabeth S Burnside; Adam Wunderlich; Frank W Samuelson; John M Boone
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2016-03-24

6.  Comparative statistical properties of expected utility and area under the ROC curve for laboratory studies of observer performance in screening mammography.

Authors:  Craig K Abbey; Brandon D Gallas; John M Boone; Loren T Niklason; Lubomir M Hadjiiski; Berkman Sahiner; Frank W Samuelson
Journal:  Acad Radiol       Date:  2014-04       Impact factor: 3.173

7.  Relationship between Roe and Metz simulation model for multireader diagnostic data and Obuchowski-Rockette model parameters.

Authors:  Stephen L Hillis
Journal:  Stat Med       Date:  2018-04-02       Impact factor: 2.373

8.  Quantification of LV function and mass by cardiovascular magnetic resonance: multi-center variability and consensus contours.

Authors:  Avan Suinesiaputra; David A Bluemke; Brett R Cowan; Matthias G Friedrich; Christopher M Kramer; Raymond Kwong; Sven Plein; Jeanette Schulz-Menger; Jos J M Westenberg; Alistair A Young; Eike Nagel
Journal:  J Cardiovasc Magn Reson       Date:  2015-07-28       Impact factor: 5.364

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.